Literature analysis of ADR after the listing of apatinib

JIN Bingjin; WU Xuehua; WANG Xin; ZHANG Yiwei; SONG Changqing; WANG Yafeng

doi:10.6039/j.issn.1001-0408.2024.07.12

您当前的位置：

首页 >

文章列表页 >

Literature analysis of ADR after the listing of apatinib

更新时间：2025-09-25

- Literature analysis of ADR after the listing of apatinib
- ZHONGGUO YAOFANG Vol. 35, Issue 7, Pages: 837-841(2024)
- 作者机构：
  
  青海省人民医院药学部，西宁　810007
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.07.12
  CLC： R969.3;R979.1
- Received：31 August 2023，
  
  Revised：2024-03-18，
  
  Accepted：18 March 2024，
  
  Published：15 April 2024
- 稿件说明：
移动端阅览
金秉巾,吴雪花,王欣,等.阿帕替尼上市后的ADR文献分析[J].中国药房,2024,35(07):837-841.

JIN Bingjin,WU Xuehua,WANG Xin,et al.Literature analysis of ADR after the listing of apatinib[J].ZHONGGUO YAOFANG,2024,35(07):837-841.
金秉巾,吴雪花,王欣,等.阿帕替尼上市后的ADR文献分析[J].中国药房,2024,35(07):837-841. DOI： 10.6039/j.issn.1001-0408.2024.07.12.

JIN Bingjin,WU Xuehua,WANG Xin,et al.Literature analysis of ADR after the listing of apatinib[J].ZHONGGUO YAOFANG,2024,35(07):837-841. DOI： 10.6039/j.issn.1001-0408.2024.07.12.

摘要

目的

探讨阿帕替尼所致药物不良反应（ADR）的特点及规律，为其临床安全用药提供参考。

方法

检索自阿帕替尼2014年上市以来，中国知网、万方医学网、维普及PubMed等中英文数据库中关于其ADR及安全性评估的个案和群体报道，经筛选后对文献资料进行提取及分析。

结果

共纳入病例101例，涉及ADR 221例次。发生ADR的患者中，男女比例为1.24∶1，年龄以51～70岁最多，给药剂量以500 mg及以上者居多，但其中给予小剂量阿帕替尼并联合使用了其他抗肿瘤药物的患者也较易发生ADR。ADR的种类以1～2种居多，而种类最多者可高达6种。该药的ADR多发生在用药后30 d内，累及器官/系统以心血管系统损害、皮肤及其附件损害、胃肠系统损害和泌尿系统损害为主，主要临床表现为高血压/加重、手足综合征、腹痛腹泻和蛋白尿等，其严重ADR以高血压/加重、手足综合征和骨髓抑制多见。多数ADR均可通过停药、减量及对症处理实现好转/痊愈。4例死亡患者均存在基础病，且美国东部肿瘤协作组评分均≥2分。特殊ADR（如可逆性后部脑病综合征、精神异常和认知障碍等）多由阿帕替尼自身引起，亦存在阿帕替尼与原发疾病或基础疾病共同引起的可能。

结论

高龄、剂量较大、联合用药、存在基础病及体力状态不佳是使用阿帕替尼患者发生ADR的高危因素。建议对所有使用该药患者的血压、尿蛋白及手足皮肤进行日常监测，并注意特殊ADR的发生，以便及时发现并给予有效干预，从而避免ADR加重及继发其他ADR。

Abstract

OBJECTIVE

To explore the characteristics and regulations of adverse drug reactions （ADR） caused by apatinib， and to provide a reference for the safe use of apatinib in clinic.

METHODS

Case and group reports on ADR and safety evaluation of apatinib were retrieved from Chinese and English databases such as CNKI， Wanfang medical network， VIP and PubMed since its listing in 2014， literature data were extracted and statistically analyzed after screening.

RESULTS

Totally 101 cases were included， involving 221 ADR. In the above cases， the male-to-female ratio was 1.24∶1， with the highest proportion of patients aged 51 to 70 years， most of the patients were given a dose of 500 mg or more， and the patients given low dose of apatinib combined with other antitumor drugs were also likely to have ADR. One to two types of adverse reaction were the most common， while the types could reach up to six. Most ADR occurred within 30 days after medication， and the systems/organs involved were mainly the cardiovascular system damage，skin and its accessories damage， gastrointestinal system damage and urinary system damage； the main clinical manifestations were hypertension/aggravation，hand-foot syndrome，abdominal pain diarrhea and albuminuria， etc. Hypertension/aggravation， hand-foot syndrome and myelosuppression were the most common serious ADR. Most ADR could be improved/cured by suspension of administration， dose downregulation and symptomatic treatment. All 4 patients who died had underlying diseases， and their ECOG scores all ≥2 points. Special ADR （such as reversible posterior encephalopathy syndrome， psychiatric disorders， and cognitive impairment） were mostly caused by apatinib itself， or may be caused by apatinib in combination with the primary or underlying disease.

CONCLUSIONS

Advanced age， large dose， combination medication， underlying diseases and poor physical condition might be the high risks for ADR caused by apatinib. It is recommended to monitor the blood pressure，urine protein and skin of hands and feet of all patients with medication on a daily basis，pay attention to the occurrence of special ADR， and timely detect abnormal states and give effective intervention，so as to avoid the aggravation of ADR and other secondary ADR.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

PETRELLI F ， GHIDINI M ， BARNI S ， et al . Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma：a systematic review and meta-analysis [J ] . Gastric Cancer ， 2019 ， 22 （ 2 ）： 245 - 254 .

XIE C F ， ZHOU X ， LIANG C H ， et al . Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer [J ] . J Exp Clin Cancer Res ， 2021 ， 40 （ 1 ）： 266 .

曹竣博，王莫然，王硕，等 . 一种新型靶向药物甲磺酸阿帕替尼的研究进展 [J ] . 广东化工， 2022 ， 49 （ 5 ）： 64 - 66 .

CAO J B ， WANG M R ， WANG S ， et al . Research pro- gress of apatinib mesylate as a new targeted drug for the treatment of surgical diseases such as gallbladder cancer [J ] . Guangdong Chem Indus ， 2022 ， 49 （ 5 ）： 64 - 66 .

CHEN D S ， ZHONG X Z ， LIN L ， et al . Comparative efficacy and adverse reactions of apatinib-chemotherapy combinations versus chemotherapy alone for treatment of advanced colorectal cancer：a meta-analysis of randomized controlled trials [J ] . Am J Transl Res ， 2022 ， 14 （ 9 ）： 6703 - 6711 .

DUECK A C ， MENDOZA T R ， MITCHELL S A ， et al . Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events （PRO-CTCAE） [J ] . JAMA Oncol ， 2015 ， 1 （ 8 ）： 1051 - 1059 .

中华人民共和国卫生部，国家食品药品监督管理局 . 药品不良反应报告和监测管理办法 [EB/OL ] .（ 2004-03-04 ）[ 2023-07-21 ] . http：//www.nhc.gov.cn/wjw/bmgz/200804/8fd34a2690c04eeeb266856bf364931e.shtml http://www.nhc.gov.cn/wjw/bmgz/200804/8fd34a2690c04eeeb266856bf364931e.shtml .

Ministry of Health of the People’s Republic of China ， State Food and Drug Administration . Measures for the reporting and monitoring of adverse drug reactions [EB/OL ] .（ 2004-03-04 ）[ 2023-07-21 ] . http：//www.nhc.gov.cn/wjw/bmgz/200804/8fd34a2690c04eeeb266856bf364931e.shtml http://www.nhc.gov.cn/wjw/bmgz/200804/8fd34a2690c04eeeb266856bf364931e.shtml .

秦叔逵，李进 . 阿帕替尼治疗胃癌的临床应用专家共识 [J ] . 临床肿瘤学杂志， 2015 ， 20 （ 9 ）： 841 - 847 .

QIN S K ， LI J . Expert consensus on clinical application of apatinib in the treatment of gastric cancer [J ] . Chin Clin Oncol ， 2015 ， 20 （ 9 ）： 841 - 847 .

朱盼荣，梁利军，夏铀铀，等 . 阿帕替尼联合多靶点抗原肽自体免疫细胞治疗肾癌后腹膜淋巴结转移一例 [J ] . 中国肿瘤生物治疗杂志， 2018 ， 25 （ 3 ）： 315 - 317 .

ZHU P R ， LIANG L J ， XIA Y Y ， et al . A patient with renal carcinoma and retroperitoneal lymph node metastasis treated by apatinib combined with multiple antigen stimulating cellular therapy [J ] . Chin J Cancer Biother ， 2018 ， 25 （ 3 ）： 315 - 317 .

王伟星，胡毅，饶智国，等 . 阿帕替尼治疗患者出现甲状腺功能减退2例 [J ] . 中国肿瘤临床， 2017 ， 44 （ 22 ）： 1167 - 1168 .

WANG W X ， HU Y ， RAO Z G ， et al . Two cases of hypothyroidism in patients treated with apatinib [J ] . Chin J Clin Oncol ， 2017 ， 44 （ 22 ）： 1167 - 1168 .

GABORA K ， PICIU A ， BĂDULESCU I C ， et al . Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors [J ] . Drug Metab Rev ， 2019 ， 51 （ 4 ）： 562 - 569 .

叶红，李军杰，武力勇 . 重视新型抗肿瘤药物相关可逆性后部脑病综合征 [J ] . 药物不良反应杂志， 2021 ， 23 （ 5 ）： 225 - 227 .

YE H ， LI J J ， WU L Y . Emphasize the reversible posterior encephalopathy syndrome associated with new anti-tumor drugs [J ] . Adverse Drug React J ， 2021 ， 23 （ 5 ）： 225 - 227 .

梁雪峰，盛立军，王文辉，等 . 阿帕替尼三线治疗胃癌致胃瘘一例报告 [J ] . 中华肿瘤防治杂志， 2018 ， 25 （ 3 ）： 213 - 214，220 .

LIANG X F ， SHENG L J ， WANG W H ， et al . A case report of apatinib in the third-line treatment of gastric fistula caused by gastric cancer [J ] . Chin J Cancer Prev Treat ， 2018 ， 25 （ 3 ）： 213 - 214，220 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Vedolizumab-associated lung toxicity：a case report and literature analysis

Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis

Related Author

LIANG Yu

DING Xueli

WU Jun

QUAN Xianghua

ZHAO Jun

ZHANG Chuanzhou

JIANG Man

WANG Feng

Related Institution

Dept. of Pharmacy， the Affiliated Hospital of Qingdao University

Dept. of Gastroenterology， the Affiliated Hospital of Qingdao University

Dept. of Pharmacy， Fudan University Shanghai Cancer Center

Dept. of Clinical Oncology， Shanghai Medical College of Fudan University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰